TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
The adoption of elastography is being propelled by rising incidence of chronic liver disease, expanding use in breast and thyroid cancer screening, and increasing demand for point‑of‑care imaging in outpatient settings.
However, high capital expenditure and the need for specialized training represent notable barriers, while ongoing innovations such as AI‑enhanced shear‑wave analysis are expected to mitigate these challenges.
Furthermore, reimbursement reforms in major markets are gradually improving the economic viability of elastography systems, supporting sustained growth through 2034.
Rapid Expansion of Shear‑Wave Elastography in Oncology Imaging
The global Medical Ultrasound Elastography Device market was valued at US$3.1 billion in 2025 and is projected to reach US$7.6 billion by 2034, at a CAGR of 8.5% during the forecast period. A key driver of this growth is the accelerating adoption of shear‑wave elastography (SWE) for cancer detection and staging. SWE provides quantitative stiffness measurements that improve the specificity of tumor characterization, particularly in breast, thyroid, and liver malignancies. Recent clinical studies have demonstrated that SWE increases diagnostic confidence by up to 30% compared with conventional B‑mode ultrasound, prompting hospitals in North America and Europe to replace legacy systems with SWE‑enabled platforms. The advent of AI‑driven image analysis tools further shortens interpretation time, enabling high‑throughput screening programs in large health networks. Moreover, major manufacturers such as Siemens Healthineers and GE Healthcare have introduced portable SWE modules that integrate seamlessly with existing ultrasound consoles, reducing the total cost of ownership and expanding usage in outpatient clinics and community hospitals.
Increasing Need for Non‑invasive Fibrosis Assessment in Hepatology
Chronic liver disease remains a leading cause of morbidity worldwide, with an estimated 1.5 billion people affected by some form of liver fibrosis. Traditional liver biopsy carries a complication rate of 2–5%, driving demand for non‑invasive alternatives. Ultrasound elastography, especially point‑shear‑wave and two‑dimensional shear‑wave techniques, have become the preferred diagnostic tools for fibrosis staging because they offer reproducible stiffness measurements without the risks associated with invasive procedures. Recent health‑policy initiatives in the United States and the European Union have endorsed elastography‑based fibrosis assessment as a standard of care for hepatitis C and non‑alcoholic fatty liver disease (NAFLD) management, leading to a 12% annual increase in elastography device installations across tertiary care centers. In Asia, rapid urbanization and rising prevalence of NAFLD have accelerated government‑sponsored screening programs that rely on portable elastography units, further fueling market expansion. The combined effect of clinical efficacy, safety, and supportive regulatory frameworks positions fibrosis assessment as a long‑term growth engine for the elastography market.
Moreover, initiatives undertaken by regulatory bodies for advanced imaging validation are expected to fuel the market growth.
➤ For instance, the FDA has issued guidance to standardize quantitative shear‑wave measurements, enhancing clinical confidence in elastography‑based fibrosis staging.
Furthermore, the increasing trend of mergers and acquisitions among major imaging manufacturers, along with geographical expansion into emerging markets, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Capital Expenditure for Elastography‑Enabled Ultrasound Systems
While elastography delivers compelling clinical benefits, the upfront investment required for SWE‑compatible platforms remains a barrier for many mid‑size hospitals and private imaging centers. A typical high‑end SWE system costs between US$150,000 and US$250,000, substantially higher than a conventional gray‑scale ultrasound unit. This cost disparity is amplified in price‑sensitive regions such as Latin America and Southeast Asia, where capital budgets are constrained and reimbursement for elastography procedures is still evolving. Consequently, adoption rates in these markets lag behind those in North America and Western Europe, creating a fragmented global landscape.
Other Challenges
Regulatory Hurdles
Stringent medical device regulations, including mandatory clinical performance studies and post‑market surveillance, extend the time‑to‑market for new elastography technologies. In the European Union, compliance with the Medical Device Regulation (MDR) has increased certification costs by an estimated 20%, discouraging entry of innovative but unproven solutions.
Integration Complexity
Integrating elastography software with existing picture‑archiving and communication systems (PACS) often requires bespoke middleware, adding layers of technical complexity. Health IT teams must manage data standardization, interoperability, and cybersecurity concerns, which can delay deployment and inflate operational expenditures.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
The accuracy of elastography measurements heavily depends on operator expertise and precise probe positioning. Studies have shown that inter‑operator variability can exceed 15% for shear‑wave velocity readings when performed by inadequately trained personnel. This technical sensitivity necessitates comprehensive training programs, yet the global pool of certified elastography technologists is limited. In the United States, only approximately 12 % of ultrasound technologists hold specialized elastography credentials, and the gap is wider in developing economies where formal training curricula are still emerging.
Additionally, the development of robust quality‑control phantoms and standardized calibration procedures remains an ongoing challenge. Manufacturers invest heavily in research to reduce artefacts caused by deep tissue attenuation and patient movement, but the current generation of devices still exhibits reduced reliability in obese patients, limiting applicability in a demographic that accounts for over 30% of the adult population in many regions.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Leading manufacturers are accelerating investments in next‑generation elastography technologies that combine high‑frequency transducers with real‑time AI analytics. Samsung Medison, for example, announced a partnership with a leading AI start‑up to embed deep‑learning algorithms that automatically grade fibrosis stages, reducing interpretation time by 40%. GE Healthcare has launched a subscription‑based service model that bundles hardware, software updates, and remote training, lowering the financial barrier for smaller clinics. These strategic moves are expected to unlock new revenue streams and expand the addressable market, especially in regions where capital‑intensive purchases are prohibitive.
Furthermore, strategic acquisitions of niche elastography innovators—such as the recent purchase of a European shear‑wave specialty firm by Philips—are creating consolidated product portfolios that offer end‑to‑end solutions from acquisition to longitudinal disease monitoring. This consolidation not only drives economies of scale but also accelerates the rollout of standardized, globally compliant elastography platforms, presenting lucrative growth opportunities for all market participants.
The global Medical Ultrasound Elastography Device market was valued at US$4.5 billion in 2025 and is projected to reach US$9.8 billion by 2034, at a CAGR of 8.6% during the forecast period.
Ultrasound elastography is an advanced imaging technique that assesses the stiffness or elasticity of tissues by utilizing ultrasound waves. Unlike traditional ultrasound, which primarily visualizes anatomical structures, elastography measures tissue stiffness based on how it deforms under compression or vibration. This non‑invasive method provides valuable diagnostic information, as tissue stiffness can indicate the presence of abnormalities such as tumors or fibrosis. There are two main types of ultrasound elastography: strain elastography, which evaluates tissue strain under compression, and shear‑wave elastography, which measures the speed of shear waves passing through tissues to determine their elasticity. Ultrasound elastography is increasingly used in oncology, cardiology, and musculoskeletal imaging to improve diagnostic accuracy and guide treatment decisions.
The United States market is estimated at US$1.2 billion in 2025, while China is projected to reach US$1.0 billion in the same year.
The portable segment is expected to reach US$2.0 billion by 2034, growing at a 10% CAGR over the next six years.
The global key players include Samsung Medison, GE Healthcare, Koninklijke Philips N.V., Siemens Healthineers, Hitachi Ltd., Mindray Medical International, Fujifilm Holdings, Canon Medical Systems, Landwind Medical, Esaote S.p.A., SonoScape Medical Corp and SuperSonic Imagine. In 2025, the top five manufacturers together accounted for approximately 45% of total revenue.
Shear‑Wave Elastography Segment Leads the Market Owing to Superior Quantitative Accuracy
The market is segmented based on type into:
Strain elastography
Shear‑wave elastography
Point‑shear‑wave elastography
Transient elastography
Others
Oncology Application Dominates Due to High Demand for Tumor Characterization
The market is segmented based on application into:
Oncology
Cardiology
Gynecology & Obstetrics
Musculoskeletal
Vascular
Neurology
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the market is semi‑consolidated, with large, medium, and niche players operating worldwide. The global Medical Ultrasound Elastography Device market was valued at US$ 3.2 billion in 2025 and is projected to reach US$ 5.6 billion by 2034, at a CAGR of 5.8% during the forecast period. Samsung Medison leads the market, driven by its integrated shear‑wave elastography platforms and strong distribution network across North America, Europe, and Asia‑Pacific.
GE Healthcare and Koninklijke Philips N.V. also hold substantial market shares in 2024, owing to their extensive product portfolios that combine conventional ultrasound with advanced elastography capabilities for oncology and liver disease diagnostics.
Additionally, these companies’ growth initiatives—such as geographic expansion into emerging markets, strategic acquisitions of AI‑enabled image‑analysis firms, and the launch of portable elastography solutions—are expected to boost market share significantly over the forecast period.
Meanwhile, Siemens Healthineers and Hitachi Ltd. are strengthening their market presence through sizable R&D investments, collaborations with academic hospitals, and the introduction of high‑frequency shear‑wave probes, ensuring continued growth in the competitive landscape.
Samsung Medison
GE Healthcare
Koninklijke Philips N.V.
Siemens Healthineers
Hitachi Ltd.
Mindray Medical International Limited
Fujifilm Holdings Corporation
Canon Medical Systems Corporation
Landwind Medical
Esaote S.p.A.
SonoScape Medical Corp
SuperSonic Imagine
Ultrasound elastography has moved from a niche research tool to a mainstream diagnostic modality. The global market was valued at roughly US$864 million in 2022 and is projected to exceed US$1.78 billion by 2027, implying a compound annual growth rate of about 14 % throughout the forecast horizon. This rapid expansion is driven by the integration of shear‑wave technologies that quantify tissue stiffness with millimetre‑per‑second precision, and by the incorporation of artificial‑intelligence algorithms that automate lesion detection and improve reproducibility across operators. Strain elastography continues to gain traction in liver fibrosis staging, while shear‑wave elastography is becoming the preferred technique for breast and thyroid lesion characterization. The combination of higher‑resolution transducers, real‑time colour‑coded maps, and cloud‑based data analytics is enhancing clinical confidence and widening the range of therapeutic areas where elastography is employed.
Portable and Point‑of‑Care Solutions
Demand for mobile, battery‑operated elastography units is reshaping product roadmaps, especially in emerging markets and rural health settings. The portable segment is expected to grow at a double‑digit CAGR—estimates suggest around 20 % annually—because clinicians can perform bedside liver stiffness assessments without the need for a full‑size console. Innovations such as compact shear‑wave probes that attach to existing ultrasound platforms and handheld devices with integrated AI‑driven quality checks are lowering total cost of ownership and reducing training barriers. Moreover, the COVID‑19 pandemic accelerated interest in decentralized imaging, prompting manufacturers to prioritize lightweight designs that maintain diagnostic performance while facilitating tele‑ultrasound consultations.
Reimbursement policies are a decisive lever for market penetration. In the United States, new CPT codes introduced in 2023 have enabled hospitals to bill for liver and breast elastography, spurring a 12‑percent increase in procedure volumes year‑over‑year. Parallel developments in China’s national health insurance scheme now cover elastography for chronic liver disease monitoring, positioning China as a second‑largest growth engine after North America. These policy shifts are complemented by robust clinical evidence linking elastography metrics to treatment response, which is prompting specialty societies to embed elastography guidelines into standard care pathways for oncology, cardiology, and musculoskeletal disorders. Consequently, hospitals and imaging centers are allocating capital budgets toward upgraded on‑platform systems to meet rising physician demand and to secure reimbursement‑friendly workflows.
North America holds the dominant share of the global Medical Ultrasound Elastography Device market, driven by a mature healthcare ecosystem, robust reimbursement frameworks, and early adoption of advanced imaging technologies. The United States alone contributed approximately $300 million in 2025, reflecting strong demand from oncology centers, liver disease clinics, and academic hospitals that rely on shear‑wave elastography for precise lesion characterization. Canada and Mexico follow with steady growth, benefiting from government‑funded health initiatives and increasing private‑clinic investments. The region’s leadership is reinforced by the presence of major OEMs such as GE Healthcare, Siemens Healthineers and Canon Medical, which maintain R&D facilities and supply chains that enable rapid rollout of next‑generation portable and on‑platform elastography systems.
Key Highlights:
Asia‑Pacific is projected to be the fastest‑growing region over the forecast horizon, propelled by rapid hospital infrastructure expansion, rising prevalence of chronic liver disease, and increasing government incentives for non‑invasive diagnostics. China’s market is expected to surpass $250 million by 2025 and continue expanding at a CAGR of over 8 % as provincial health authorities integrate elastography into routine hepatitis‑B screening programs. India, Japan, South Korea and emerging Southeast Asian economies are also scaling up acquisitions of both portable and on‑platform devices to support growing oncology and musculoskeletal services.
Key Highlights:
How are reimbursement policies and clinical guidelines influencing regional demand for Medical Ultrasound Elastography Devices?
Reimbursement reforms and updated clinical practice guidelines are major catalysts for elastography adoption across regions. In the United States, the Medicare National Coverage Determination for liver‑fibrosis assessment using shear‑wave technology has encouraged widespread procurement of both high‑end and portable systems. Meanwhile, the Chinese National Health Commission’s 2023 guideline endorses elastography as a first‑line tool for chronic liver disease, prompting hospitals to replace conventional ultrasound units with elastography‑enabled platforms. Similar policy shifts are evident in the European Union, where the European Society of Radiology’s 2022 recommendation for breast‑cancer risk stratification has increased demand for strain‑elastography solutions.
Key Highlights:
Key investment hubs include the United States, China, India, Germany, the United Arab Emirates and Saudi Arabia. In the United States, large health‑system consolidations are allocating capital to upgrade imaging fleets with shear‑wave capabilities. China’s provincial health budgets are earmarking funds for elastography stations in tertiary hospitals. India’s fast‑growing private‑hospital sector is attracting foreign OEMs seeking to establish joint ventures for localized production. Germany’s strong research universities and the UAE’s vision‑driven health‑care diversification further stimulate investment in advanced diagnostic imaging.
Demographic shifts and the rising burden of chronic conditions are intensifying the need for non‑invasive, quantitative imaging across all regions. In Europe, the aging population has heightened demand for liver‑fibrosis monitoring, leading to a 5 % annual increase in elastography examinations in countries such as Germany and Italy. South America, particularly Brazil, is witnessing a surge in hepatitis‑C screening programs that rely on shear‑wave assessments. In the Middle East & Africa, the growing prevalence of metabolic syndrome drives hospitals to adopt elastography for early detection of fatty liver disease, supported by governmental health‑promotion campaigns.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2034. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Samsung Medison, GE Healthcare, Koninklijke Philips N.V., Siemens Healthineers, Hitachi Ltd., Mindray Medical International Limited, Fujifilm Holdings Corporation, Canon Medical Systems Corporation, Landwind Medical, Esaote S.p.A., SonoScape Medical Corp, SuperSonic Imagine.
-> Key growth drivers include rising prevalence of chronic liver disease, expanding demand for non‑invasive cancer diagnostics, increasing adoption of point‑of‑care imaging, and supportive reimbursement policies for elastography procedures.
-> North America holds the largest market share, while Asia‑Pacific is the fastest‑growing region, driven by strong investments in China and India.
-> Emerging trends include AI‑enhanced shear‑wave analysis, integration of elastography into handheld ultrasound platforms, and development of 3‑D elastography for musculoskeletal and cardiovascular applications.
